Table 3.
Significantly enriched molecular pathways at year 2, by functional category (immune response, inflammation, other)
| Category | Lower expression in the abatacept arm | Lower expression in the adalimumab arm | ||
|---|---|---|---|---|
| MetaCore pathway description | Genes | MetaCore pathway description | Genes | |
| Immune response | Antigen presentation | 18/197 | Phagocytosis | 16/222 |
| T-helper cell differentiation | 14/139 | BCR pathway | 10/137 | |
| TCR signaling | 15/174 | Phagosome in antigen presentation | 13/243 | |
| Phagosome in antigen presentation | 14/243 | Th17-derived cytokines | 7/98 | |
| Antigen presentation | 10/197 | |||
| TCR signaling | 8/174 | |||
| Inflammation | NK cell cytotoxicity | 17/164 | Amphoterin (HMG1) signaling | 15/118 |
| IL-4 signaling | 9/115 | IL-10 anti-inflammatory response | 11/87 | |
| JAK-STAT pathway | 10/186 | Protein C signaling | 11/108 | |
| Neutrophil activation | 15/215 | |||
| IL-6 signaling | 11/119 | |||
| IL-2 signaling | 10/104 | |||
| Innate inflammatory response | 11/180 | |||
| Histamine signaling | 11/213 | |||
| Inflammasome | 8/118 | |||
| IgE signaling | 8/137 | |||
| IFN-gamma signaling | 7/109 | |||
| TREM1 signaling | 8/145 | |||
| IL-4 signaling | 7/115 | |||
| Kallikrein–kinin system | 9/185 | |||
| MIF signaling | 7/140 | |||
| IL-12,-15,-18 signaling | 4/59 | |||
| Other | Proliferation: lymphocyte proliferation | 15/210 | Cell cycle: G1-S IL regulation | 12/128 |
| Cell cycle: G2M | 13/206 | Chemotaxis | 11/137 | |
| Cell adhesion: leukocyte chemotaxis | 12/180 | Cell cycle: G1-S growth factor regulation | 11/195 | |
| Cell cycle: core | 9/115 | Cell adhesion: platelet–endothelium–leukocyte interactions | 10/174 | |
| Cell cycle: mitosis | 11/179 | Development: regulation of angiogenesis | 11/222 | |
| DNA damage: DSB repair | 8/116 | Apoptosis: anti-apoptosis mediated by external signals via PI3K/AKT | 11/233 | |
| Cell cycle: S phase | 9/149 | Development: blood vessel morphogenesis | 10/228 | |
| Chemotaxis | 8/137 | Reproduction: feeding and neurohormone signaling | 9/210 | |
| Cytoskeleton: actin filaments | 8/176 | |||
| Muscle contraction: relaxin signaling | 5/82 | |||
| Signal transduction: nitric oxide signaling | 5/88 | |||
| Cell adhesion: integrin-mediated cell–matrix adhesion | 8/214 | |||
All pathways shown are statistically significantly enriched (FDR adjusted p value < 0.05)
BCR B-cell receptor, DSB double-strand break, FDR false discovery rate, HMG1 high-mobility group protein 1, IFN interferon, IgE immunoglobulin E, IL interleukin, JAK-STAT Janus kinase-signal transducer and activator of transcription, MIF macrophage migration inhibitory factor, NK natural killer, PI3K/AKT phosphatidylinositol 3-kinase/protein kinase B, TCR T cell receptor, Th17 T helper 17, TREM1 Triggering Receptor Expressed on Myeloid Cells 1
Reprinted from ACR Convergence held November 3–8, 2017. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Bristol Myers Squibb